Global Markets Direct’s, ‘Idiopathic Juvenile Arthritis (Still’s Disease) – Pipeline Review, H2 2015′, provides an overview of the Idiopathic Juvenile Arthritis (Still’s Disease)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Idiopathic Juvenile Arthritis (Still’s Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Juvenile Arthritis (Still’s Disease) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Idiopathic Juvenile Arthritis (Still’s Disease)
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Idiopathic Juvenile Arthritis (Still’s Disease) and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Idiopathic Juvenile Arthritis (Still’s Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Idiopathic Juvenile Arthritis (Still’s Disease) pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Idiopathic Juvenile Arthritis (Still’s Disease)
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Idiopathic Juvenile Arthritis (Still’s Disease) pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Idiopathic Juvenile Arthritis (Still's Disease) Overview 8
Therapeutics Development 9
Pipeline Products for Idiopathic Juvenile Arthritis (Still's Disease) - Overview 9
Pipeline Products for Idiopathic Juvenile Arthritis (Still's Disease) - Comparative Analysis 10
Idiopathic Juvenile Arthritis (Still's Disease) - Therapeutics under Development by Companies 11
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Idiopathic Juvenile Arthritis (Still's Disease) - Products under Development by Companies 15
Idiopathic Juvenile Arthritis (Still's Disease) - Companies Involved in Therapeutics Development 16
Biocon Limited 16
Epirus Biopharmaceuticals, Inc. 17
Genor BioPharma Co., Ltd. 18
Hetero Drugs Limited 19
Mabion SA 20
Mycenax Biotech Inc. 21
Oncobiologics, Inc. 22
Oncodesign SA 23
Panacea Biotec Limited 24
Pfizer Inc. 25
Sandoz International GmbH 26
Swedish Orphan Biovitrum AB 27
Therapeutic Proteins International, LLC 28
UCB S.A. 29
Idiopathic Juvenile Arthritis (Still's Disease) - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
adalimumab biosimilar - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
adalimumab biosimilar - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
adalimumab biosimilar - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
adalimumab biosimilar - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
adalimumab biosimilar - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
adalimumab biosimilar - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
adalimumab biosimilar - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
adalimumab biosimilar - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
adalimumab biosimilar - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
anakinra (recombinant) - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
certolizumab pegol - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
DNX-514 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
etanercept biosimilar - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
etanercept biosimilar - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
etanercept biosimilar - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
etanercept biosimilar - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Small Molecules to Inhibit RIP2 for Crohn's Disease and Polyarthritis - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
tocilizumab biosimilar - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
tocilizumab biosimilar - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
tocilizumab biosimilar - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
tofacitinib - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Idiopathic Juvenile Arthritis (Still's Disease) - Recent Pipeline Updates 71
Idiopathic Juvenile Arthritis (Still's Disease) - Dormant Projects 86
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 87
Disclaimer 88

List of Tables

Number of Products under Development for Idiopathic Juvenile Arthritis (Still's Disease), H2 2015 9
Number of Products under Development for Idiopathic Juvenile Arthritis (Still's Disease) - Comparative Analysis, H2 2015 10
Number of Products under Development by Companies, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Comparative Analysis by Unknown Stage Development, H2 2015 14
Products under Development by Companies, H2 2015 15
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Biocon Limited, H2 2015 16
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 17
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Genor BioPharma Co., Ltd., H2 2015 18
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Hetero Drugs Limited, H2 2015 19
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Mabion SA, H2 2015 20
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Mycenax Biotech Inc., H2 2015 21
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Oncobiologics, Inc., H2 2015 22
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Oncodesign SA, H2 2015 23
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Panacea Biotec Limited, H2 2015 24
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Pfizer Inc., H2 2015 25
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Sandoz International GmbH, H2 2015 26
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Swedish Orphan Biovitrum AB, H2 2015 27
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Therapeutic Proteins International, LLC, H2 2015 28
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by UCB S.A., H2 2015 29
Assessment by Monotherapy Products, H2 2015 30
Number of Products by Stage and Target, H2 2015 32
Number of Products by Stage and Mechanism of Action, H2 2015 34
Number of Products by Stage and Route of Administration, H2 2015 36
Number of Products by Stage and Molecule Type, H2 2015 38
Idiopathic Juvenile Arthritis (Still's Disease) Therapeutics - Recent Pipeline Updates, H2 2015 71
Idiopathic Juvenile Arthritis (Still's Disease) - Dormant Projects, H2 2015 86

List of Figures

Number of Products under Development for Idiopathic Juvenile Arthritis (Still's Disease), H2 2015 9
Number of Products under Development for Idiopathic Juvenile Arthritis (Still's Disease) - Comparative Analysis, H2 2015 10
Number of Products under Development by Companies, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 12
Comparative Analysis by Early Stage Products, H2 2015 13
Assessment by Monotherapy Products, H2 2015 30
Number of Products by Top 10 Targets, H2 2015 31
Number of Products by Stage and Top 10 Targets, H2 2015 31
Number of Products by Top 10 Mechanism of Actions, H2 2015 33
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 33
Number of Products by Top 10 Routes of Administration, H2 2015 35
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 35
Number of Products by Top 10 Molecule Types, H2 2015 37
Number of Products by Stage and Top 10 Molecule Types, H2 2015 37